In this study, we show that reduced expression of both E-cadherin and DSG2 is observed in primary prostate cancer, and that this reduced expression is significantly associated with a shorter biochemical recurrence (BCR)-free survival, rendering both classical and desmosomal cadherins as markers of poor prognosis in patients with prostate cancer. The gene discussed is DSG2; the disease is prostate carcinoma.